This page lists the SEC filings reported by Broadfin Capital, LLC.
Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
---|---|---|---|---|---|---|
SC 13G/A | 2017-02-13 | Broadfin Capital, LLC | Advaxis, Inc. | 1,519,259 | 3.8% | EDGAR |
SC 13G/A | 2017-02-13 | Broadfin Capital, LLC | RXi Pharmaceuticals Corp | 250,000 | 2.8% | EDGAR |
SC 13G/A | 2017-02-13 | Broadfin Capital, LLC | ANTARES PHARMA, INC. | 12,971,093 | 8.4% | EDGAR |
SC 13G/A | 2017-02-13 | Broadfin Capital, LLC | ADMA BIOLOGICS, INC. | 1,113,293 | 8.6% | EDGAR |
SC 13G/A | 2017-02-13 | Broadfin Capital, LLC | CATALYST PHARMACEUTICALS, INC. | 8,200,000 | 9.9% | EDGAR |
SC 13G/A | 2017-02-13 | Broadfin Capital, LLC | Egalet Corp | 1,228,751 | 4.8% | EDGAR |
SC 13G/A | 2017-02-13 | Broadfin Capital, LLC | NEVRO CORP | 43,281 | 0.2% | EDGAR |
SC 13G/A | 2017-02-13 | Broadfin Capital, LLC | BioLineRx Ltd. | 0 | 0.0% | EDGAR |
SC 13G/A | 2017-02-13 | Broadfin Capital, LLC | Aevi Genomic Medicine, Inc. | 3,370,306 | 9.1% | EDGAR |
SC 13G/A | 2017-02-13 | Broadfin Capital, LLC | VERACYTE, INC. | 1,788,266 | 5.4% | EDGAR |
SC 13G/A | 2017-02-13 | Broadfin Capital, LLC | Ignyta, Inc. | 2,256,546 | 5.4% | EDGAR |
SC 13G/A | 2017-02-13 | Broadfin Capital, LLC | PROGENICS PHARMACEUTICALS INC | 8,951,169 | 12.8% | EDGAR |
SC 13G/A | 2017-02-13 | Broadfin Capital, LLC | BIODELIVERY SCIENCES INTERNATIONAL INC | 5,398,794 | 10.0% | EDGAR |
SC 13G/A | 2017-02-13 | Broadfin Capital, LLC | ARATANA THERAPEUTICS, INC. | 3,695,442 | 10.0% | EDGAR |
SC 13G/A | 2017-02-13 | Broadfin Capital, LLC | AmpliPhi Biosciences Corp | 68,000 | 0.4% | EDGAR |
SC 13G/A | 2017-02-13 | Broadfin Capital, LLC | Aviragen Therapeutics, Inc. | 3,486,711 | 9.0% | EDGAR |
SC 13G/A | 2017-02-13 | Broadfin Capital, LLC | Aralez Pharmaceuticals Inc. | 4,791,590 | 7.3% | EDGAR |
SC 13G/A | 2017-02-13 | Broadfin Capital, LLC | ALCOBRA LTD. | 2,057,106 | 7.5% | EDGAR |
SC 13G/A | 2017-02-13 | Broadfin Capital, LLC | ANGIODYNAMICS INC | 1,471,152 | 4.0% | EDGAR |
SC 13G/A | 2017-02-10 | Broadfin Capital, LLC | LA JOLLA PHARMACEUTICAL CO | 1,510,316 | 8.3% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.